Vulvar Lichen Sclerosus
1
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2024
2025
2026
StratpharmaStrataMGT
StratpharmaStrataMGT
Clinical Trials (2)
Total enrollment: 105 patients across 2 trials
StrataMGT in the Reduction of Vulvar Lichen Sclerosus (LS) Symptoms
Start: Oct 2024Est. completion: Oct 2025100 patients
Phase 1Recruiting
StrataMGT for the Treatment of Vulvar Lichen Sclerosus
Start: Apr 2024Est. completion: Nov 20245 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 105 patients
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.